{"name":"Prescient Therapeutics, Ltd.","slug":"prescient-therapeutics-ltd","ticker":"","exchange":"","domain":"prescient.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Triciribine","genericName":"Triciribine","slug":"triciribine","indication":"Other","status":"discontinued"}]}],"pipeline":[{"name":"Triciribine","genericName":"Triciribine","slug":"triciribine","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNUDlmLW5YNEdIemJzdFg2SGw3ekFrREczV08ta1VySWZOQ2ZET3h2MFZSeW5Eby1fNzBHc3B0S3Jld1VmRnVfbnlKLUw3dnR3M004OEQyTXVvbjhoUHdlZWNoNzgxbnpWOW8taE1EeFlSeUVSMUVxUU04LTliV0hWY3hNMXRGd1FCMl9zc2c1TXNGWTg?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Segmentation, Major Trends, and Competitive Overview of the Anaplastic Large Cell Lymphoma Therapeutics Market - openPR.com","headline":"Segmentation, Major Trends, and Competitive Overview of the Anaplastic Large Cell Lymphoma Therapeutics Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNZ0padGxqWEdyYVQ1X21KcDhrRHd0RDg1VUU4a2dySGw5SDBaNkpTNjd3UGdmNDBQSTlDWjBqSzRoeWx4VWpSMTlsUGVFeTdzMzQ1R3RPc3VnMWJNTkNNTnNmbW1EOHhhZHRkZFBhUVRjRy1iRzFmWV9JQ3hlaWFEdlJqQzduV0pzOEFLWDR1SlEtTURkM3dLS2xNWmtoNHhaelNDLXRxUEo2ZWRValNDeVBPRkhKMTdBeU5LVUROUVJTZ3BsTkZEc2VFaDJPNGtJbTZiNnh2Wi1MQVZXUmw0?oc=5","date":"2025-12-14","type":"trial","source":"proactiveinvestors.com","summary":"Prescient Therapeutics clears path to begin PTX-100 lymphoma trial in Italy - proactiveinvestors.com","headline":"Prescient Therapeutics clears path to begin PTX-100 lymphoma trial in Italy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQcVdTZHZ5MWtfRUhMQXhOTkU0amZDNy16aUtkdmZHYXJZX1RleFNEQ0QxUEFha3pUNTFfR3hHUjljamFadzBFU2xUa0ZTWDRMUFNNR2pJZm1fQUgyMXl0N0FLWTZwdm9MbUF0UFNxUGhtV0NmRl9NOXMtVUlFZkJ4V3pMTWswQjZXVTVXdHZFYkM5NDBPSHBmd0VVb2NFWENjYzhBRUwtbFJTY2trQ3VIZE1WVkxTOHZtNHVZMXJCVmNSeUxra0JTUlBKblZFSXZrV1d5QlFVbk9aeDhlNnE1XzFHLWZ6R2NRa1RSak5kSElkSWZlRlltaUViaHZTY1lrMFN0a2RB?oc=5","date":"2025-11-26","type":"pipeline","source":"PR Newswire","summary":"Mycosis Fungoides Market Set to Expand by 2034 with Advancements in Targeted and Immunotherapy Approaches | DelveInsight - PR Newswire","headline":"Mycosis Fungoides Market Set to Expand by 2034 with Advancements in Targeted and Immunotherapy Approaches | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxOTFFERExJa3E5UkNDN1d6MFE0V1RaeFA5akRDOWwtdkpBbnVXb1UzbkVFU2dxOUJnOUR1S2xPZXlPdVBqeDlqTTFjaEF2S2pULWNGSGpnVHhnbjEyZ0ZyZlhNMHVJVEJ4ekduN25MdGlZZDd4WUwzLXBLQW1qZ2tWVXpFOUROcDhyQVdSS2RLcWdSM3pVSWl4Y2RpRXhxWjV4VmlkbnJVMnRTLTIzd25nMG5CLXZlb1B0OHVIaDFDZm1YS2xpZ2hxc3MyUFk5dm5tM213a0ExSU5YYzJiTTZQdGFrOA?oc=5","date":"2025-08-08","type":"pipeline","source":"proactiveinvestors.com","summary":"Inside Biotech: US orphan drug policy a silver lining for rare disease research - proactiveinvestors.com","headline":"Inside Biotech: US orphan drug policy a silver lining for rare disease research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxPRVd6WXpfckdJZGoxTUJaOGRyaXpqcXgzX1RSS0xmRFp6MEx5NUJqQkZfaW5rQTRSMDBJWG9mZ2ZnQUMtZl9WTkhoNFdiZ1hyekYxUXczTzhhZlZtd1ZsSWg0d2plTnZPU3pUY0xsR0g0MnQ2OGUtcXdzOExuaEhJdDNoMGRLZ0owUzZ0WHFweHZRZnlrODBud0htTzUwcndEb1A2QzdQb3dOTFBMSGM3MmJCZEVmZmthNmdibmN6MnBNYmtFLTdNSzl3X2FZSmUyN3lNemFaQ1JmNnI2dU9ZLWVMSFgyQXlzU0thSGl3ZWpDbklKbjlpelA4WEFhQTlxMzIyYlB3cHRGNWhDRnVmb0Z0NlVOSnFSU3B0Zzh0eFgtbWlGTEtlMURhNjFUd3dFMEow?oc=5","date":"2025-07-21","type":"pipeline","source":"GlobeNewswire","summary":"Cutaneous T-cell Lymphoma Market Anticipates Impressive - GlobeNewswire","headline":"Cutaneous T-cell Lymphoma Market Anticipates Impressive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPaTR1Q20yM0U0Y3NSWmNsamlReUtrUU96TmFuNzJ1ZldudUpFSFFtbnFldEpTbElPZ21jSDhkUTRTZzU0bDRRLURTUTk4bnJlN0kzZnFyYV9SbXdrODN2QTAzNGVWQ1NKajM4d1NjZWdEQWxURE1Sbk8xMDlnbDRFT3BycjhxUE5YREY5M055c3Rzbm9pNkFUMVJGQmUtRllsQjlGQ1lxdUNsa1ZGSE12Q0hkd2J5alhEemZZT2hrY1ZQMDd1bFktdnd3VWNYMnZBc0RHSXd2OHRDMlhZLU42azdzR1V4cFR4VGNsY01n?oc=5","date":"2025-07-18","type":"trial","source":"Proactive Investors","summary":"Prescient Therapeutics gains momentum with Phase 2 trial as analysts raise valuation - Proactive Investors","headline":"Prescient Therapeutics gains momentum with Phase 2 trial as analysts raise valuation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQOTNrVDVadmpSUDJ4WGRuQlJRbm9NNkgxYk5ldW0wTHd6WVl2SFZfeDN4U21rVUtWYzlRSTZfc19iQTZmdjdUZFV6blI5RllleTlMVFd1MTdiNjRKaXVPemxMZHNrQWpILXVJMm5vcG9Bdzk0eWtlVzBsR0MtMkNsTzJDLUlqTlp0V2MwNkd5QURhTkptMlFrQnpSaHN5LVlIeDNBV1Z0c3puUzdPU0pScTgzOVJTeWxJVHI0NmhjZklGdjFnbzBwT0ZGS1RSMVRHWWt5QlBYOTYxTkwtMlRhUXI5WDZEclItVDVZ?oc=5","date":"2025-06-11","type":"pipeline","source":"Proactive financial news","summary":"Prescient Therapeutics: Advancing cancer treatment with PTX-100 and cell therapies - Proactive financial news","headline":"Prescient Therapeutics: Advancing cancer treatment with PTX-100 and cell therapies","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-13","type":"pipeline","source":"simplywall.st","summary":"Is Prescient Therapeutics (ASX:PTX) In A Good Position To Invest In Growth? - simplywall.st","headline":"Is Prescient Therapeutics (ASX:PTX) In A Good Position To Invest In Growth?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1JeFhic3p4eTY0eklvSUxHY2F0NTl4R0dDY3NJSHdOdl83SHdVd0lxZUFVSERXYkkyaFpOTTRhakFmOERMNXB0ZEZtTXFONHZ2NVZPSDVEMVAxWkk3?oc=5","date":"2025-04-17","type":"regulatory","source":"EurekAlert!","summary":"Novel radiolabeled antibody developed for diagnosis and treatment of solid tumors - EurekAlert!","headline":"Novel radiolabeled antibody developed for diagnosis and treatment of solid tumors - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxOdG5HU0kwZUNwSWpYcl8wQmNEMGg1a2gya0lRN1c5SDFfWDUtZzU0ZTdtUEw2TXI2YzRpMG91NHJuYW9rZF9TUldVaHR1MU5GUkdndDF2THo1SHhna1RXXzJ1UVN2VWdqX1kxeU52dmlQeGJrd3QwZmktV3NYa3pzcjVBSTMtNGNPZU9YdHZyUXJnaFYxdlFtRElHazdzem5KMVZwY3F1WkRCMEd5eTE2b2NFNXZTMHhPT2dzc2pkLVNaYTBEdnF2OFJVbXpGM0d2eDVwSXhYMUxXcVEtT2IzaG9aYWZHLXkz?oc=5","date":"2025-01-06","type":"regulatory","source":"CRISPR Medicine News","summary":"Press Release Service: CAR-T Cell Therapy Market Research 2024-2025: Size, Forecasts, Trials, and Trends - Approved CAR-T Therapies and Late-stage Clinical Trials that Could Reach Commercialization So","headline":"Press Release Service: CAR-T Cell Therapy Market Research 2024-2025: Size, Forecasts, Trials, and Trends - Approved CAR-","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOOHV3dEVsZzFSeXlGT0QzQk03VU96VjNHVVZ4ZU0yNjBBd0ZBdXJhSzNtS2E5YTYwLTRPT191LXdackFaQXpwWVNFT2NXbHZqZ3ZOVHpYdGlnbmE5Yzh6akhNSVdHVWV5WjMtTDhRNzZVNXV2Z25OREFoZTZvRVVQVFNjSnBEaDFKTERjNF9aREFfVVVnc0dWdEdYQTlRV21VajBMNmhCaXBYWkdaMDdTQldSQUtfTHcxbGZjTGdNTmVhbnJyWEl6RWNyay1wY3k0bkh1N05GeTRUT19QcDRUeFBpeVZKem1DZG1MN195MWFiQWR3Y2lNSC1B?oc=5","date":"2024-12-17","type":"pipeline","source":"Proactive financial news","summary":"Prescient Therapeutics appoints experienced pharmaceuticals executive James McDonnell as CEO | ASX:PTX - Proactive financial news","headline":"Prescient Therapeutics appoints experienced pharmaceuticals executive James McDonnell as CEO | ASX:PTX","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPT3VfVlFfQk80STItYUc3ZGYzUmJNd2ZTa29OOW9zWW56S2NmSlQ0SC1BOXRqcTYxamtXVDJOOTJ2RUJqVHVHZzdoVGJTREU4bTFEMGh5dTNkdzhOUHVPM0RiMkszdk9keF8yZkZBQXV2enZic3FkOWEtR1FFQjlObTlqekFGV2Q1bFluTHRlTHFKaEl3Nlk4SjFrd0pJLTZuUXpTT1VqX2NqdzZ6dGg1aExoWVY2Um5vYUZwYXpoc1h2UWhFaEtsazhic0Q4SjVuX0dxY1UtcE1mbU9qWGh1OQ?oc=5","date":"2024-12-17","type":"pipeline","source":"Investing.com Australia","summary":"Prescient Therapeutics appoints experienced pharmaceuticals executive James McDonnell as CEO - Investing.com Australia","headline":"Prescient Therapeutics appoints experienced pharmaceuticals executive James McDonnell as CEO","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"discontinued":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}